Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism

• Main Authors: Wen-Jie Zhou, Jie Zhang, Hui-Li Yang, Ke Wu, Feng Xie, Jiang-Nan Wu, Yan Wang, Li Yao, Yan Zhuang, Jiang-Dong Xiang, Ai-Jun Zhang, Yin-Yan He, Ming-Qing Li
• Format: Article
• Language: English
• Published: BMC 2019-08-01
• Series: Cell Communication and Signaling
• Subjects: Uterine endometrial cancer; CB-839; Estrogen; Autophagy; Glutamine
• Online Access: http://link.springer.com/article/10.1186/s12964-019-0412-9

Abstract Background Excessive estrogen exposure is an important pathogenic factor in uterine endometrial cancer (UEC). Recent studies have reported the metabolic properties can influence the progression of UEC. However, the underlying mechanisms have not been fully elucidated. Methods Glutaminase (GLS), MYC and autophagy levels were detected. The biological functions of estrogen-MYC-GLS in UEC cells (UECC) were investigated both in vivo and in vitro. Results Our study showed that estrogen remarkably increased GLS level through up-regulating c-Myc, and enhanced glutamine (Gln) metabolism in estrogen-sensitive UEC cell (UECC), whereas fulvestrant (an ER inhibitor antagonist) could reverse these effects. Estrogen remarkably promoted cell viability and inhibited autophagy of estrogen sensitive UECC. However, CB-839, a potent selective oral bioavailable inhibitor of both splice variants of GLS, negatively regulated Gln metabolism, and inhibited the effects of Gln and estrogen on UECC’s growth and autophagy in vitro and / or in vivo. Conclusions CB-839 triggers autophagy and restricts growth of UEC by suppressing ER/Gln metabolism, which provides new insights into the potential value of CB-839 in clinical treatment of estrogen-related UEC.